Search results for "Intravitreal triamcinolone"

showing 1 items of 1 documents

Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion.

2013

Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by randomized clinical trials, intravitreal injections of ranibizumab (Lucentis; Genentech, South San Francisco, CA) constitute a new effective and safe option for the management of these vision-threatening diseases. The aim of the present review is to summarize the clinical evidence of ranibizumab for macular edema due to retinal vein occlusions.

medicine.medical_specialtyRetinal Veingenetic structuresReviewlaw.inventionRandomized controlled triallcsh:OphthalmologylawOphthalmologyOcclusionMedicineIn patientranibizumabMacular edemaIntravitreal triamcinolonemacular edemabusiness.industrymedicine.diseaseVEGFeye diseasesantiangiogenic therapylcsh:RE1-994retinal vein occlusionRetinal vein occlusionsRanibizumabbusinessBiomedical engineeringmedicine.drugOphthalmology and eye diseases
researchProduct